• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HLA-G 表达与免疫逃避性肌层浸润性膀胱癌相关,并驱动预后相关性。

HLA-G expression associates with immune evasion muscle-invasive urothelial cancer and drives prognostic relevance.

机构信息

Institute of Pathology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)), Erlangen, Germany.

CCC Erlangen-EMN: Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.

出版信息

Front Immunol. 2024 Oct 14;15:1478196. doi: 10.3389/fimmu.2024.1478196. eCollection 2024.

DOI:10.3389/fimmu.2024.1478196
PMID:39469714
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11513269/
Abstract

INTRODUCTION

Urothelial bladder cancer is frequent and exhibits diverse prognoses influenced by molecular subtypes, urothelial subtype histology, and immune microenvironments. HLA-G, known for immune regulation, displays significant membranous expression in tumor tissues.

METHODS

We studied the protein expression of Human Leucocyte Antigen G (HLA-G) in 241 Muscle-Invasive Bladder Cancer (MIBC) patients, elucidating its potential clinical and biological significance. Protein expression levels were evaluated and correlated with molecular subtypes, histological characteristics, immune microenvironment markers, and survival outcomes.

RESULTS

High HLA-G expression associates with poor overall survival (OS) and diseasespecific survival (DSS), independent of clinicopathological parameters. HLA-G expression varies among molecular subtypes and Urothelial Subtype Histology, e.g., elevated expression levels in basal/squamous MIBC and those with sarcomatoid differentiation. Notably, HLA-G is increased in MIBC with an immune evasive microenvironment (high PD-L1 tumor cell expression, NK cell depletion, granzyme B (GZMB)/CD8 ratio reduction, MHC class I (MHCI) expression reduction) that are characterized by immunosuppressive features and poor prognosis. Furthermore, HLA-G correlates with elevated levels of other immune checkpoint proteins (TIGIT, LAG3, CTLA-4), indicating its role in immune evasion.

DISCUSSION

Our findings underscore HLA-G's role as a potential prognostic marker and interesting immunotherapeutic target in MIBC. Its impact on immune evasion mechanisms and broad expression, coupled with associations withpoor survival and distinct tumor phenotypes, positions HLA-G as a promising protein for further exploration in developing targeted immunotherapies for MIBC patients.

摘要

简介

尿路上皮膀胱癌较为常见,其预后存在差异,受到分子亚型、尿路上皮组织学亚型和免疫微环境的影响。人类白细胞抗原 G(HLA-G)作为一种免疫调节蛋白,在肿瘤组织中呈现明显的膜表达。

方法

我们研究了 241 例肌层浸润性膀胱癌(MIBC)患者中 HLA-G 蛋白的表达情况,阐明了其潜在的临床和生物学意义。评估了蛋白表达水平,并与分子亚型、组织学特征、免疫微环境标志物和生存结局相关联。

结果

HLA-G 高表达与总生存(OS)和疾病特异性生存(DSS)不良相关,且独立于临床病理参数。HLA-G 的表达在分子亚型和尿路上皮组织学亚型之间存在差异,例如基底/鳞状 MIBC 和具有肉瘤样分化的患者中表达水平升高。值得注意的是,在具有免疫逃避微环境(肿瘤细胞 PD-L1 高表达、NK 细胞耗竭、颗粒酶 B(GZMB)/CD8 比值降低、MHC Ⅰ类(MHCI)表达降低)的 MIBC 中,HLA-G 表达增加,这些特点与免疫抑制特征和不良预后相关。此外,HLA-G 与其他免疫检查点蛋白(TIGIT、LAG3、CTLA-4)的水平升高相关,表明其在免疫逃避中的作用。

讨论

我们的研究结果强调了 HLA-G 作为 MIBC 潜在预后标志物和有趣的免疫治疗靶点的作用。其对免疫逃避机制的影响及其广泛表达,以及与不良生存和独特肿瘤表型的关联,使 HLA-G 成为 MIBC 患者开发靶向免疫治疗的有前途的蛋白。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805b/11513269/3465c6be8475/fimmu-15-1478196-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805b/11513269/4bc7b93d79ca/fimmu-15-1478196-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805b/11513269/dca7c57138a4/fimmu-15-1478196-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805b/11513269/3465c6be8475/fimmu-15-1478196-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805b/11513269/4bc7b93d79ca/fimmu-15-1478196-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805b/11513269/dca7c57138a4/fimmu-15-1478196-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/805b/11513269/3465c6be8475/fimmu-15-1478196-g003.jpg

相似文献

1
HLA-G expression associates with immune evasion muscle-invasive urothelial cancer and drives prognostic relevance.HLA-G 表达与免疫逃避性肌层浸润性膀胱癌相关,并驱动预后相关性。
Front Immunol. 2024 Oct 14;15:1478196. doi: 10.3389/fimmu.2024.1478196. eCollection 2024.
2
The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes.肿瘤免疫微环境驱动预后相关性,与膀胱癌亚型相关。
Cancer Immunol Res. 2019 Jun;7(6):923-938. doi: 10.1158/2326-6066.CIR-18-0758. Epub 2019 Apr 15.
3
A prognostic immune predictor, HLA-DRA, plays diverse roles in non-muscle invasive and muscle invasive bladder cancer.一个预后免疫预测因子 HLA-DRA 在非肌肉浸润性和肌肉浸润性膀胱癌中发挥多种作用。
Urol Oncol. 2021 Apr;39(4):237.e21-237.e29. doi: 10.1016/j.urolonc.2020.11.017. Epub 2020 Dec 15.
4
Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands.涎腺腺样囊性癌的免疫微环境与逃逸机制。
Oral Oncol. 2019 Jan;88:95-101. doi: 10.1016/j.oraloncology.2018.11.028. Epub 2018 Nov 23.
5
Poor clinical outcomes and immunoevasive contexture in interleukin-9 abundant muscle-invasive bladder cancer.白细胞介素-9 高表达的肌层浸润性膀胱癌临床预后差且免疫逃避。
Int J Cancer. 2020 Dec 15;147(12):3539-3549. doi: 10.1002/ijc.33237. Epub 2020 Aug 20.
6
Multi-omics analysis unveils the predictive value of IGF2BP3/SPHK1 signaling in cancer stem cells for prognosis and immunotherapeutic response in muscle-invasive bladder cancer.多组学分析揭示了 IGF2BP3/SPHK1 信号在肌层浸润性膀胱癌肿瘤干细胞中对预后和免疫治疗反应的预测价值。
J Transl Med. 2024 Oct 4;22(1):900. doi: 10.1186/s12967-024-05685-8.
7
Immune response and evasion mechanisms in lip carcinogenesis: An immunohistochemical study.在唇癌发生中的免疫反应和逃逸机制:免疫组织化学研究。
Arch Oral Biol. 2019 Feb;98:99-107. doi: 10.1016/j.archoralbio.2018.09.017. Epub 2018 Sep 29.
8
Upregulation of IFNɣ-mediated chemokines dominate the immune transcriptome of muscle-invasive urothelial carcinoma.IFNɣ 介导的趋化因子的上调主导肌层浸润性尿路上皮癌的免疫转录组。
Sci Rep. 2022 Jan 13;12(1):716. doi: 10.1038/s41598-021-04678-7.
9
Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer.肌层浸润性膀胱癌中尿路上皮向肉瘤样转化的形态学和基因组特征。
Urol Oncol. 2019 Sep;37(9):573.e19-573.e29. doi: 10.1016/j.urolonc.2019.06.021. Epub 2019 Jul 26.
10
Prognostic Significance of Immune Checkpoints HLA-G/ILT-2/4 and PD-L1 in Colorectal Cancer.免疫检查点 HLA-G/ILT-2/4 和 PD-L1 在结直肠癌中的预后意义。
Front Immunol. 2021 May 13;12:679090. doi: 10.3389/fimmu.2021.679090. eCollection 2021.

本文引用的文献

1
Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts.TACSTD2/TROP2 和 NECTIN-4/NECTIN-4 与两个晚期膀胱癌队列中分子亚型、PD-L1 表达和 FGFR3 突变状态的关联。
Histopathology. 2024 Apr;84(5):863-876. doi: 10.1111/his.15130. Epub 2024 Jan 9.
2
A luminescence-based method to assess antigen presentation and antigen-specific T cell responses for screening of immunomodulatory checkpoints and therapeutics.基于发光的方法评估抗原呈递和抗原特异性 T 细胞反应,用于筛选免疫调节检查点和治疗药物。
Front Immunol. 2023 Jul 25;14:1233113. doi: 10.3389/fimmu.2023.1233113. eCollection 2023.
3
Prognostic value of human leukocyte antigen G expression in solid tumors: a systematic review and meta-analysis.
人类白细胞抗原 G 表达在实体瘤中的预后价值:系统评价和荟萃分析。
Front Immunol. 2023 May 18;14:1165813. doi: 10.3389/fimmu.2023.1165813. eCollection 2023.
4
Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors.一种新型阻断抗体抑制 LILRB2,该抗体旨在重新编程免疫抑制性巨噬细胞,以在肿瘤中驱动 T 细胞激活。
Mol Cancer Ther. 2023 Apr 3;22(4):471-484. doi: 10.1158/1535-7163.MCT-22-0351.
5
Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition.远处转移而非配对原发性尿路上皮癌的空间免疫表型可预测对免疫检查点抑制的反应。
Eur Urol. 2023 Feb;83(2):133-142. doi: 10.1016/j.eururo.2022.10.020. Epub 2022 Nov 10.
6
Improved Bladder Tumor RNA Isolation from Archived Tissues Using Methylene Blue for Normalization, Multiplex RNA Hybridization, Sequencing and Subtyping.采用亚甲蓝进行归一化、多重 RNA 杂交、测序和分型,提高膀胱癌存档组织的 RNA 分离效率。
Int J Mol Sci. 2022 Sep 6;23(18):10267. doi: 10.3390/ijms231810267.
7
BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression.BND-22,一种首创的人源化 ILT2 阻断抗体,可促进抗肿瘤免疫和肿瘤消退。
J Immunother Cancer. 2022 Sep;10(9). doi: 10.1136/jitc-2022-004859.
8
A Novel Prognostic Risk Model for Cervical Cancer Based on Immune Checkpoint HLA-G-Driven Differentially Expressed Genes.基于免疫检查点 HLA-G 驱动的差异表达基因的宫颈癌新型预后风险模型。
Front Immunol. 2022 Jul 18;13:851622. doi: 10.3389/fimmu.2022.851622. eCollection 2022.
9
The Human Leukocyte Antigen G as an Immune Escape Mechanism and Novel Therapeutic Target in Urological Tumors.人类白细胞抗原 G 作为尿路上皮肿瘤的免疫逃逸机制和新型治疗靶点。
Front Immunol. 2022 Feb 3;13:811200. doi: 10.3389/fimmu.2022.811200. eCollection 2022.
10
Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients.空间程序性死亡配体1(PD-L1)表达与肿瘤免疫微环境的整合在预测尿路上皮癌患者预后方面优于标准PD-L1评分。
Cancers (Basel). 2021 May 12;13(10):2327. doi: 10.3390/cancers13102327.